MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-06-30, BSGM had $2,678K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$2,678K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-06-30
Net loss
-23,169
Non-cash lease expense
82
Prepaid expenses
45
Employee advances
0
Operating lease liabilities
-87
Lease receivables
0
Customer deposits
0
Accounts receivable
0
Accounts payable and accrued expenses
5,638
Impairment of long-term assets
0
Gain on settlement of debt
196
Depreciation and amortization
577
Stock based compensation
7,444
Unbilled revenue
13
Sales tax receivable
-3
Common stock issued for services rendered
-7,244
Allowance for credit losses on accounts receivable
-109
Net cash used in operating activities
-2,393
Business acquisition, net of cash acquired
-366
Net cash provided by investing activity
366
Proceeds from issuance of related party note payable
0
Sale of common stock and warrants
818
Proceeds from sale of common stock and warrants, net of issuance costs
0
Sale of common stock under at-the- market offering, net of transaction costs
3,882
Net cash provided by financing activities
4,700
Effect of exchange rate changes on cash and cash equivalents
5
Net increase in cash and cash equivalents
2,678
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

BioSig Technologies, Inc. (BSGM)

BioSig Technologies, Inc. (BSGM)